Diagnoses and Treatments of Metastatic Endometrial Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 31 May 2025 | Viewed by 810

Special Issue Editor


E-Mail Website
Guest Editor
Departments of Pathology, Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
Interests: endometrial serous carcinogenesis; endometrial cancer pathogenesis; TCGA-endometrial cancer molecular classification; targeted therapy; immune therapy; uterine sarcoma; clinical trials
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Uterine cancer stands as the most prevalent gynecologic malignancy in developed nations, presenting a significant health challenge and, despite advancements, its mortality rate continues to escalate, underscoring the urgency of further research and innovative therapeutic strategies. Contributing factors to this rising incidence are multifaceted, including hormonal imbalances, prolonged menstruation, nulliparity, advancing age, obesity, hormone therapy for breast cancer, and hereditary syndromes predisposing individuals to cancer. Of particular concern are advanced-stage or endometrial cancers with extrauterine metastasis, compounded by suboptimal therapeutic options in current clinical practice. Hence, the forthcoming issue of the journal Cancers endeavors to address this pressing concern by soliciting submissions focusing on endometrial cancer diagnosis (both pathological and imaging modalities) and management.

We invite contributions encompassing research or reviews that enhance our understanding of endometrial cancer metastasis and improve patient survival rates. Topics of interest include, but are not limited to, investigations into FIGO 2023 staging-related issues, such as the correlation of aggressive histologic types with cancer metastasis; cases of histologically low-grade endometrial cancer with recurrence or metastasis; synchronous endometrial and ovarian cancers; lymphovascular space invasion (LVSI) quantification in hysterectomy specimens; molecular classification of endometrial cancer; management strategies for POLE mutant endometrial cancers; genetic syndromes associated with endometrial cancers; targeted therapies; and immunotherapies for advanced endometrial cancers, along with the outcomes of relevant clinical trials.

In conclusion, this Special Issue aims to foster a comprehensive understanding of metastatic endometrial cancer—from diagnosis to therapy—and to provide a platform for disseminating cutting-edge research that promises to advance clinical practice and improve patient outcomes.

Prof. Dr. Wenxin Zheng
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • endometrial cancer
  • mesonephric-like adenocarcinoma
  • pilomatrix-like high-grade endometrioid carcinomas
  • endometrial carcinosarcomas showing different prognosis based on different epithelial and mesenchymal components
  • pathologic diagnosis
  • imaging studies
  • target therapy
  • clinical trials

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

9 pages, 502 KiB  
Review
Sentinel Lymph Node in Endometrial Hyperplasia: State of the Art and Future Perspectives
by Valentina Billone, Lina De Paola, Eleonora Conti, Letizia Borsellino, Zoltan Kozinszky, Pierluigi Giampaolino, Andrea Suranyi, Luigi Della Corte, Alessandra Andrisani, Gaspare Cucinella, Susanna Marinelli and Giuseppe Gullo
Cancers 2025, 17(5), 776; https://doi.org/10.3390/cancers17050776 - 24 Feb 2025
Viewed by 461
Abstract
Background/Objectives: Endometrial hyperplasia is a uterine pathology characterized by the abnormal proliferation of endometrial glands, resulting in an increased gland-to-stroma ratio. Complex atypical hyperplasia represents the primary precursor to endometrial cancer. Given the high risk of progression to endometrial adenocarcinoma, the accurate [...] Read more.
Background/Objectives: Endometrial hyperplasia is a uterine pathology characterized by the abnormal proliferation of endometrial glands, resulting in an increased gland-to-stroma ratio. Complex atypical hyperplasia represents the primary precursor to endometrial cancer. Given the high risk of progression to endometrial adenocarcinoma, the accurate diagnosis and classification of endometrial hyperplasia are crucial. Since the treatment for atypical endometrial hyperplasia is the same as that for early-stage endometrial cancer (i.e., total hysterectomy and bilateral salpingo-oophorectomy), researchers have questioned whether sentinel lymph node mapping could also have a prognostic role in atypical endometrial hyperplasia. Methods: A literature search was conducted in PubMed and Scopus from 2014 to 2025. Of the 65 papers found, 31 relevant articles were selected based on inclusion criteria, focusing on sentinel lymph node staging in patients with atypical endometrial hyperplasia. This review aims to assess whether sentinel lymph node mapping can be routinely used for prognostic and therapeutic purposes in clinical practice. Results: Sentinel lymph node biopsy represents a promising diagnostic technique for patients with atypical endometrial hyperplasia, reducing the need for invasive procedures and postoperative risks. However, its application requires advanced surgical skills and access to specific technologies, raising ethical and financial concerns, while future studies could improve patient selection and the reliability of the procedure through technological innovations. Conclusions: Sentinel lymph node biopsy is a safe and effective method for staging early-stage endometrial cancer and atypical hyperplasia, with low metastasis rates, but future research should focus on identifying patients who would benefit most from this procedure, considering its costs and required expertise. Full article
(This article belongs to the Special Issue Diagnoses and Treatments of Metastatic Endometrial Cancer)
Show Figures

Figure 1

Back to TopTop